| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Daniels Ronald J serves as a Director at BBIO. Across recent SEC filings that breaks down to 2 buys and 2 sells. Those positions are worth an estimated $1.8M at current prices.
Historically, Daniels Ronald J's trades have earned a below-average insider score of 19/100 across 3 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -48.7%.
The biggest single holding is BBIO (~$1.8M) as Director. The recent filings there lean toward selling, a net 50,629 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 6, 2025 | BBIO Bridgebio Pharma, Inc. | Director | Sale+OE | 61,031 | $63.72 | $3,888,999.07 | -78.2% | +19.9% | - | |
| Dec 30, 2021 | BBIO Bridgebio Pharma, Inc. | Director | Buy | 22,147 | $13.49 | $298,678.53 | New | -28.7% | -47.6% | |
| Dec 28, 2021 | BBIO Bridgebio Pharma, Inc. | Director | Sell | 11,745 | $12.80 | $150,336.00 | -100% | -22.3% | -49.8% |